148983-03-3

Basic information

• Product Name: (S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-cyclohexylpropanoic acid
• Synonyms: (S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-cyclohexylpropanoic acid;(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)(m...;(αS)-α-[[(9H-Fluoren-9-ylmethoxy)carbonyl]methylamino]cyclohexanepropanoic acid;(9H-Fluoren-9-yl)MethOxy]Carbonyl N-Me-Cha-OH;(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-cyclohexylpropanoic
• CAS NO: 148983-03-3
• Molecular Formula: C₂₅H₂₉NO₄
• Molecular Weight: 407.50206
• Mol File: 148983-03-3.mol

Chemical Properties

• Boiling Point: 588.5±29.0 °C(Predicted)
• Appearance: /
• Density: 1.198±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 3.92±0.10(Predicted)
• CAS DataBase Reference: (S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-cyclohexylpropanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-cyclohexylpropanoic acid(148983-03-3)
• EPA Substance Registry System: (S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-cyclohexylpropanoic acid(148983-03-3)

Safety Data

• Hazardous Substances Data: 148983-03-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-cyclohexylpropanoic acid is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique structure and functional groups may contribute to the development of new therapeutic agents with improved efficacy and selectivity.
Used in Organic Synthesis:
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-cyclohexylpropanoic acid is used as a building block in the synthesis of complex organic molecules. Its reactivity and structural features can be exploited to create novel compounds with potential applications in various fields.
Used in Biological Research:
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-cyclohexylpropanoic acid may be used as a probe or tool in biological research to study the interactions of specific enzymes or receptors. Its unique structure and functional groups can help elucidate the mechanisms of biological processes and identify potential therapeutic targets.
Used in Drug Delivery Systems:
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-cyclohexylpropanoic acid can be used in the development of drug delivery systems to improve the bioavailability and therapeutic efficacy of various drugs. Its structural features can be utilized to design targeted drug carriers or enhance drug solubility and stability.

Upstream product

• 135673-97-1 (S)-3-cyclohexyl-2-(9H-fluoren-9-ylmethoxycarbonylamino)propionic acid 

Downstream Products

• 148983-04-4 ((S)-1-tert-Butylcarbamoyl-2-cyclohexyl-ethyl)-methyl-carbamic acid 9H-fluoren-9-ylmethyl ester 
• 148983-05-5 (2S)-α-(methylamino)-N-(1,1-dimethylethyl)cyclohexanepropionamide 

Relevant articles and documents

Metabolically stable apelin-analogues, incorporating cyclohexylalanine and homoarginine, as potent apelin receptor activators

High blood pressure and consequential cardiovascular diseases are among the top causes of death worldwide. The apelinergic (APJ) system has emerged as a promising target for the treatment of cardiovascular issues, especially prevention of ischemia reperfusion (IR) injury after a heart attack or stroke. However, rapid degradation of the endogenous apelin peptides in vivo limits their use as therapeutic agents. Here, we study the effects of simple homologue substitutions, i.e. incorporation of non-canonical amino acids l-cyclohexylalanine (l-Cha) and l-homoarginine (l-hArg), on the proteolytic stability of pyr-1-apelin-13 and apelin-17 analogues. The modified 13-mers display up to 40 times longer plasma half-life than native apelin-13 and in preliminary in vivo assay show moderate blood pressure-lowering effects. The corresponding apelin-17 analogues show pronounced blood pressure-lowering effects and up to a 340-fold increase in plasma half-life compared to the native apelin-17 isoforms, suggesting their potential use in the design of metabolically stable apelin analogues to prevent IR injury. This journal is

Discovery of Novel Nonpeptidic PAR2 Ligands

Proteinase-activated receptor 2 (PAR2) is a class A G protein-coupled receptor whose activation has been associated with inflammatory diseases and cancer, thus representing a valuable therapeutic target. Pathophysiological roles of PAR2 are often characterized using peptidic PAR2 agonists. Peptidic ligands are frequently unstable in vivo and show poor bioavailability, and only a few approaches toward drug-like nonpeptidic PAR2 ligands have been described. The herein-described ligand 5a (IK187) is a nonpeptidic PAR2 agonist with submicromolar potency in a functional assay reflecting G protein activation. The ligand also showed substantial β-arrestin recruitment. The development of the compound was guided by the crystal structure of PAR2, when the C-terminal end of peptidic agonists was replaced by a small molecule based on a disubstituted phenylene scaffold. IK187 shows preferable metabolic stability and may serve as a lead compound for the development of nonpeptidic drugs addressing PAR2.

Influence of lipophilicity on the biological activity of cyclic pseudopeptide NK-2 receptor antagonists

A series of cyclic pseudopeptides of the formula cyclo(LeuΨ[CH2NH]Xaa- Gln-Trp-Phe-βAla), where Xaa represents the residue of an α-amino acid, has been synthesized in order to establish the role of the Xaa side chain for tachykinin NK-2 recepto